| Dr Mark Grogan Tusa, MD | |
|
409 W Adams Ave, Temple, TX 76501-4211 | |
| (254) 742-3775 | |
| Not Available |
| Full Name | Dr Mark Grogan Tusa |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 20 Years |
| Location | 409 W Adams Ave, Temple, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033395074 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | M8395 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Memorial Healthcare System, Inc | Chattanooga, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Chattanooga Skin And Cancer Clinic | 9032386354 | 12 |
News Archive
Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced the enrollment and dosing of the first subject in its Phase 2 trial with CB-183,315, an antibacterial drug candidate intended to treat patients with a severe and sometimes life-threatening diarrhea caused by Clostridium difficile known as C. difficile-associated diarrhea, or CDAD. The trial is expected to enroll more than 200 subjects at 28 sites in the United States and Canada.
AstraZeneca today announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted regulatory submissions for review of the investigational drug vandetanib in the treatment of patients with advanced medullary thyroid cancer (MTC). The FDA also granted priority review status for the new drug application and set a Prescription Drug User Fee Act (PDUFA) action date of 7 January 2011.
Researchers at the University of Florida, USA, led by Dr. K. Wang have demonstrated that inhibition of Rho-associated kinase (ROCK) and subsequent cofilin dephosphorylation is mediating neurite outgrowth in PC12 cells.
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products, today announced that Amgen Inc. has licensed the exclusive right to use the Company's maytansinoid Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics to an undisclosed target found on solid tumors.
Competitive Technologies, Inc. held its annual meeting of shareholders today at the Hilton Stamford Hotel and Executive Meeting Center in Stamford, Conn. John B. Nano, CTT's Chairman, President and CEO reviewed the company's performance and highlighted the exciting progress on its sales and distribution plan for its Calmare pain therapy medical device, and other selected technologies.
› Verified 8 days ago
| Entity Name | Chattanooga Skin & Cancer Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447343694 PECOS PAC ID: 9032386354 Enrollment ID: O20120126000715 |
News Archive
Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced the enrollment and dosing of the first subject in its Phase 2 trial with CB-183,315, an antibacterial drug candidate intended to treat patients with a severe and sometimes life-threatening diarrhea caused by Clostridium difficile known as C. difficile-associated diarrhea, or CDAD. The trial is expected to enroll more than 200 subjects at 28 sites in the United States and Canada.
AstraZeneca today announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted regulatory submissions for review of the investigational drug vandetanib in the treatment of patients with advanced medullary thyroid cancer (MTC). The FDA also granted priority review status for the new drug application and set a Prescription Drug User Fee Act (PDUFA) action date of 7 January 2011.
Researchers at the University of Florida, USA, led by Dr. K. Wang have demonstrated that inhibition of Rho-associated kinase (ROCK) and subsequent cofilin dephosphorylation is mediating neurite outgrowth in PC12 cells.
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products, today announced that Amgen Inc. has licensed the exclusive right to use the Company's maytansinoid Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics to an undisclosed target found on solid tumors.
Competitive Technologies, Inc. held its annual meeting of shareholders today at the Hilton Stamford Hotel and Executive Meeting Center in Stamford, Conn. John B. Nano, CTT's Chairman, President and CEO reviewed the company's performance and highlighted the exciting progress on its sales and distribution plan for its Calmare pain therapy medical device, and other selected technologies.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mark Grogan Tusa, MD 409 W Adams Ave, Temple, TX 76501-4211 Ph: (254) 742-3775 | Dr Mark Grogan Tusa, MD 409 W Adams Ave, Temple, TX 76501-4211 Ph: (254) 742-3775 |
News Archive
Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced the enrollment and dosing of the first subject in its Phase 2 trial with CB-183,315, an antibacterial drug candidate intended to treat patients with a severe and sometimes life-threatening diarrhea caused by Clostridium difficile known as C. difficile-associated diarrhea, or CDAD. The trial is expected to enroll more than 200 subjects at 28 sites in the United States and Canada.
AstraZeneca today announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted regulatory submissions for review of the investigational drug vandetanib in the treatment of patients with advanced medullary thyroid cancer (MTC). The FDA also granted priority review status for the new drug application and set a Prescription Drug User Fee Act (PDUFA) action date of 7 January 2011.
Researchers at the University of Florida, USA, led by Dr. K. Wang have demonstrated that inhibition of Rho-associated kinase (ROCK) and subsequent cofilin dephosphorylation is mediating neurite outgrowth in PC12 cells.
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products, today announced that Amgen Inc. has licensed the exclusive right to use the Company's maytansinoid Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics to an undisclosed target found on solid tumors.
Competitive Technologies, Inc. held its annual meeting of shareholders today at the Hilton Stamford Hotel and Executive Meeting Center in Stamford, Conn. John B. Nano, CTT's Chairman, President and CEO reviewed the company's performance and highlighted the exciting progress on its sales and distribution plan for its Calmare pain therapy medical device, and other selected technologies.
› Verified 8 days ago
Dr. David Ford Butler, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 409 W Adams Ave, Temple, TX 76501 Phone: 254-742-3775 | |
Natalie Brittan Lane, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2401 S 31st St, Temple, TX 76508 Phone: 254-724-2111 | |
Katelen Korty, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2401 S 31st St, Temple, TX 76508 Phone: 254-724-2111 | |
Saadeddine S Saad, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2401 S 31st St # Ms 01161b, Temple, TX 76508 Phone: 254-724-8797 | |
Cecil Jordan Staples, MD Dermatology Medicare: Medicare Enrolled Practice Location: 2401 S 31st St, Temple, TX 76508 Phone: 254-724-2111 | |
Dr. Betsy J. Furukawa, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2401 S 31st St, Temple, TX 76508 Phone: 254-724-2111 |